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Background: Translational biomedical research relies on the availability of human tissue to explore disease aetiology
and prognostic factors, with the objective of developing better targeted treatments. The establishment of biobanks
poses ongoing ethical considerations in relation to donors. This is a quantitative study exploring medical oncology
patients’ preferences for contributing to tissue biobanks.
Methods: The objectives of this study were to explore oncology patients’ preferences about tissue banking, including:
1) willingness to donate; 2) factors influencing donation decisions; 3) preferences about the use of donated tissue
including permission systems, data linkage, and communication about research findings to donors. A cross-sectional
survey was conducted in two tertiary oncology outpatient clinics. Eligible patients were approached by volunteers to
complete a touchscreen survey in waiting rooms or while receiving intravenous therapy. Consenting participants
completed demographic questions and received up to 12 previously validated items exploring preferences for
donating tissue.
Results: 224 oncology outpatients participated over a ten month period (69.1 % consent rate; 64.4 % completion rate).
Most participants were female (54 %), were a mean age of 62 years, and diagnosed with breast (26 %) and bowel
(20 %) cancer. Most participants indicated willingness to donate tissue (84 %) and for their sample to be stored for
future use (96 %). Participants preferred a blanket consent approach (71 %), samples to be linked to medical records
(62 %) and for general results of the research (79 %) to be provided to them. Factors influencing willingness to donate
tissue included personal (85 %) or familial health benefits (88 %) and a sense of duty to future patients (82 %).
Conclusions: The overwhelming majority of oncology patients are willing to participate in a tissue bank, providing
some support to explore ‘opt-out’ models of consent. To enhance patient acceptability, tissue banking programs
should: (i) consider allowing blanket informed consent as well as opt-in models of consent; (ii) develop protocols
allowing feedback of information about samples in line with patient preferences; (iii) provide clear information to
potential donors about the benefits arising from donation.
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Tissue banking involves the collection and storage of
patient tissue samples for future biomedical research [1].
Banking of human tissue is an important tool for advan-
cing translational research, allowing the study of genes,
RNA and proteins to explore the biological mechanisms
that underpin disease aetiology and biology, and the* Correspondence: Jamie.Bryant@newcastle.edu.au
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unless otherwise stated.development of novel treatments [2]. In cancer, biobank-
ing and the research that follows has capacity to facilitate
more personalised therapies, with greater likelihood of
benefit and fewer adverse effects. Given that patients who
have been diagnosed with cancer may be more likely to
experience some degree of benefit from biobanking, and
can provide tissues of most interest to translational
biomedical research, there is a critical need to understand
potential donors’ willingness to participate in tissue bank-
ing, the factors influencing their decisions, and their
preferences for how their samples are used.This is an Open Access article distributed under the terms of the Creative
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ness to donate tissue for storage in a biobank, with rates
ranging from 34 to 94 % [3–5]. In contrast, the willingness
of patients with cancer to donate to biobanks is typically
higher and less variable between studies, with rates ran-
ging from 80 to 100 % [6, 7]. However, to date, research
regarding the willingness of cancer patients to donate
tissue is limited, largely qualitative, and confined to North
America and Europe [4, 8, 9].
The factors affecting potential donors’ decision-making
are unclear. Demographic factors including higher socio-
economic status [3, 5], having any tertiary or college-level
education [3, 10], being a patient [4], prior history of
disease [10], higher levels of physical functioning [3], and
previous experience providing samples [5, 10] have all
been shown to be associated with greater willingness to
donate. Few studies have explored more specific reasons
that may influence patients’ decisions to donate tissue
samples. For example, Lee and colleagues asked patients
(a minority with a history of cancer) undergoing screening
for breast cancer hypothetical questions regarding the
donation of blood and saliva to a biobank [10]. Factors
reported by respondents as influencing their decision to
donate included feeling that donation would help patients
with cancer (42.3 %) or advance science (34.6 %). Fewer
considered benefit to themselves (15.3 %) or their family
(13.7 %) as factors influencing their decision to donate.
The majority of those that indicated they would decline
the opportunity to donate cited privacy reasons (22.3 %)
and no perceived personal benefit (19.6 %) as the main
reasons. Patients with cancer have reported similar views,
though this group has typically focused on altruistic moti-
vations, as the most important factor when deciding to
donate tissue [7].
Biobanks are intended to provide a resource to allow
exploration of future as well as current research hy-
potheses. Research questions may require small or large
sample sizes, and linkage to demographic and clinical
data allows significant additional value, with an individ-
ual donation having the potential to be used for mul-
tiple projects over many years. This raises significant
ethical considerations around informed consent for use
of tissue samples [11–14], particularly as patients fre-
quently provide enough tissue to cover the needs of
several research projects [1, 12, 15]. The World Health
Organisation [16] recommends that tissue banking
studies request informed consent for all future research
at the time of tissue donation, with the view that this
blanket approval will reduce disruption to patients and
increase the efficiency of translational research. How-
ever, a single overarching consent is not universally
adopted by ethical governance boards or government
policy [17]. Alternative consent processes that have
been suggested include allowing patients to specifylimits for sample use, and gaining informed consent for
each project.
There is limited research about cancer patients’ pref-
erences regarding what information is provided to them
when requesting their consent for donation. A small
study (n = 30) of patients with various cancer diagnoses
found that 77 % would prefer to give blanket approval
for use of donated samples, with only a minority of
patients preferring to provide consent each time their
sample was used [6]. A larger study (n = 100) of
leukaemia patients reported that one-time blanket
consent (59.6 %) was preferred compared to a tiered
consent approach where patients could select the types
of studies the sample could be used in (30.3 %), and
re-consenting for each additional study (10.1 %) [18].
However, there is a need to explore the preferences of
patients with a wider range of cancers.
The linking of stored samples to medical records
raises the prospect of delivering relevant individualised
information back to biobank contributors, which is
appealing to most biobanking participants [5], and is
associated with increased willingness to participate in
biobanking among the general public [19, 20]. However,
the specific views of cancer patients about linking to
medical records remain unclear. There is also limited
knowledge regarding patients’ preferences for receiving
information about research studies that have utilised
their tissue samples. Master and colleagues [18] re-
ported that most patients with cancer preferred that
the information be passed on to themselves and their
doctor. However, they did not report on patients’ pref-
erences for the level of detail provided. For example, in-
dividuals may wish to receive only detailed information
resulting from their specific tissue sample donation;
only grouped and non-specific results generated by all
samples within the research project; or both sets of
information.
A greater understanding of the factors that influence
patient decisions to donate tissue to abiobank and prefer-
ences for the use of their donated samples is critical to the
development of appropriate and acceptable biobanking
protocols in Australia.
Aims
This study aimed to examine medical oncology patient
preferences about tissue banking, including:
a) Willingness to donate tissue to be used in research;
b) Factors influencing decisions to donate tissue; and
c) Preferences about the use of donated tissue,
including (i) the type of patient permission required
for use; (ii) linking of tissue samples to identifiable
medical records; and (iii) communication of findings
from research using tissue samples back to donors.
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Design
A cross-sectional survey was conducted with patients at-
tending two tertiary medical oncology outpatient clinics in
New South Wales, Australia.
Participant eligibility
Eligible patients were: (i) able to read English; (ii) aged
18 years of age or older; (iii) attending a participating
oncology outpatient centre for a consultation with a
healthcare provider or to receive intravenous chemother-
apy; and (iv) able to provide informed consent.
Recruitment
Participants were approached by a trained research volun-
teer in the waiting room or treatment area of the medical
oncology outpatient clinics. Volunteers provided a scripted
overview of the study. Only general information on survey
content was provided to reduce the potential to bias indi-
viduals’ decision to participate. Eligible patients were given
a study information sheet and invited to complete the
survey while waiting for their appointment or receiving
treatment. Participants could pause or end the survey if
they were called into their appointment before completion
with the option of approaching the volunteer after their
appointment to continue. Research volunteers kept a log of
the number of patients who agreed and declined participa-
tion to allow determination of consent rate. Reason for
non-participation was not recorded. Ethics approval was
provided by the Hunter New England Human Research
Ethics Committee (HNEHREC 12/08/15/4.04) and the
Newcastle Private Medical Advisory Committee.
Data collection
Surveys were administered via a tablet computer. Ques-
tions about tissue banking were part of a larger multi-site
study which included three survey modules (in order of
presentation): (i) the Consumer Preferences Survey where
respondents identified possible changes that could improve
their personal experience of care in the outpatient clinic
{Fradgley EA, 2014 #25}; (ii) willingness to participate in
future research, where respondents indicated their willing-
ness to be contacted about future research opportunities;
and, iii) willingness and preferences for tissue banking.
Only items related to tissue banking will be reported here.
In the first 14 months of data collection, medical oncology
participants received all three survey modules. After this
time, the Consumer Preferences Survey module was re-
moved and participants received the remaining two mod-
ules. The biobanking questions were always presented last.
Demographic details
Participants self-reported gender; date of birth; marital
status; highest level of education obtained; Aboriginaland/or Torres Strait Islander status; private health insur-
ance coverage; and possession of a healthcare or conces-
sion card (which entitles the holder to government
subsided medical care).
Disease and treatment characteristics
Participants were asked to self-report: the site of their
primary cancer; time since receiving their diagnosis; the
reason for their attendance at the outpatient clinic at the
time of survey completion; and their frequency of clinic
attendance over the previous 3 months.
Willingness and preferences for tissue banking
Twelve items exploring patient preferences for participating
in tissue banking were selected from measures adminis-
tered in previous studies [21]. These items were developed
by Cousins and colleagues [22] and Kettis-Lindblad and
colleagues [23] and have been tested in general populations
and donor samples to ensure items are valid, relevant, and
clearly worded.
All participants were asked whether they were willing
for tissue left over from surgery to be used in research
approved by an ethics committee (response options: yes;
depends on the type of tissue; no; unsure). Those who
agreed to donate samples, indicated it would depend on
type of tissue, or were unsure, were considered as poten-
tially willing to donate. Only those participants who
were potentially willing to donate were asked whether
they would allow remaining left-over tissue to be stored
for future research (response options: yes; no; unsure).
These participants also received the following questions:
(1) Factors influencing decisions to donate tissue. Partici-
pants answered five items assessing the factors that would
influence their decision for tissue to be used for research
(response options: yes; no; unsure). (2) Preferred permis-
sion: Participants were asked to indicate their opinion
about which system of consent should be used for stored
tissue from three options: i) a system where the person
must provide consent for each separate study their sample
will be used in (i.e., repeat consent); ii) a system where the
person gives permission once for all current and future
studies (i.e., blanket consent); iii) a system where the per-
son can choose either repeat or blanket consent. Partici-
pants were also asked how they would personally prefer to
be asked for permission (response options: prefer to be
asked each time; prefer to give permission once; unsure).
(3) Linking of tissue samples to identifiable medical
records. Participants were asked whether they would pre-
fer a sample they had given to be linked to their medical
record; unlinked; or no preference. Participants were told
that “linked” meant their sample is given a code number
that is confidential and only available to research staff,
which can be linked to their name or medical records.
Participants were told that ‘unlinked’ meant their sample




Gender (n = 223)
Male 98 44.0
Female 125 56.0
Marital Status (n = 224)
Single or never married 24 11.0
Marred or living with partner 155 69.0
Separated or divorced 28 13.0-
Widowed 17 7.6
Highest level of education (n = 222)
High school (year 10/school certificate or lower) 101 45.0
Higher school certificate 24 11.0
Diploma or trade certification 52 23.0
Bachelor degree 30 14.0
Post graduate degree 15 6.8
Aboriginal and/or Torres Strait Islander origin (n = 223)
Yes 5 2.2
No 218 98.0
Private health insurance coverage (n = 224)
Yes 99 44.0
No 125 56.0
Health care card (n = 224)
Yes 144 64.0
No 80 36.0
*All columns do not sum to 224 due to missing data
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cannot be traced back to their name or medical records.
Participants were told that linked samples are of much
greater value. (4) Communication of findings from research
using tissue samples back to donors. Participants answered
one item about whether they would prefer general
information regarding the results of studies their tissue
sample was used in to be reported back to them (re-
sponse options: yes; no; unsure). All participants were
asked if they had ever been asked for permission to use
a tissue sample for research following a routine or
planned medical procedure (response options: yes; no;
unsure). For those that had been approached, partici-
pants were asked to indicate if they have given permis-
sion (response options: yes; no; unsure).
Data analysis
Categorical measures were summarised using frequencies
and percentages. Continuous measures were summarised
using means and standard deviations.
Results
Consent rate
Of 504 medical oncology outpatients approached to par-
ticipate over a 10 month period from March to December
2013, 348 agreed to complete the survey (69.1 % consent
rate). A total of 224 patients (64.4 % of the total sample
recruited) completed demographic items, disease and
treatment items, and indicated preferences for tissue
banking participation, and were included in the analysis.
Demographic, disease and treatment characteristics
Participants were an average of 62 years old (SD = 14);
females were slightly over-represented (56 %) (Table 1).
The majority of participants were married or living with
a partner (69 %), did not have private health insurance
(56 %), and possessed a health care or concession card
(64 %). A small proportion of the sample indicated they
were of Aboriginal and/or Torres Strait Islander origin
(2.2 %). The most common primary cancer types were
breast (26 %) and bowel (20 %) (Table 2). The most
common reported reasons for attending the clinic were
related to a diagnosed cancer, with 29 % of participants
attending for a routine exam and 54 % attending to
receive tests or treatments. The majority of participants
(51.6 %) indicated they had attended the clinic on a
monthly or bimonthly basis in the preceding three months.
Willingness for tissue to be used in research
The majority of participants (84 %) indicated they would
allow their left-over tissue to be used in research approved
by an ethics committee, while 2.7 % reported their deci-
sion would depend on the type of tissue and 5.8 % wereunsure (Table 3). Moreover, 96 % of participants who indi-
cated that they would allow left-over tissue to be used also
indicated they would allow remaining tissue used in the
initial study to which they provided consent to be stored
for future use. Thirty-five participants (17 % of the total
sample) reported having been asked for permission to use
their tissue sample for research following a medical pro-
cedure in the past, and all reported that they provided per-
mission for their sample to be used.Factors influencing decisions for tissue to be used
Possible benefits to the health of family in the future
(88 %), to the individual’s own health (85 %), and benefit
to future patients (82 %) were factors the majority of
participants indicated would influence their decision to
participate in tissue banking (Table 4). Eighteen percent
of participants were concerned that refusing to donate
tissue might negatively affect the care they received and/
or their relationships with healthcare staff.
Table 2 Sample disease and treatment characteristics
(n = 224*)
Number (%)
Site of primary cancer (n = 210)
Breast 54 26.0
Bowel 43 20.0
Blood (haematological) 23 11.0
Prostate 13 6.2
Gynaecological 14 6.7




Don’t know 5 2.4
Time since diagnosis (n = 210)
Three months or less 37 18.0
Four to six months 28 13.0
Six to twelve months 40 19.0
More than 12 months 49 23.0
More than three years 56 27.0
Reason for attendance at clinic (n = 222)
For a regular check up 64 29.0
To discuss symptoms for an
undiagnosed cancer
13 5.9
To discuss symptoms for an
diagnosed cancer
25 11.0
To receive tests or treatments for a
diagnosed cancer
120 54.0
Frequency of attendance at clinic in
last 3 months (n = 224)
First time at clinic 20 8.9
First visit in last 3 months, but
attended within last 12 months
27 12.0
One previous visit 29 13.0
Two-three previous visits 52 23.0
Four to five previous visits 48 21.0
Six previous visits 17 7.6
Seven or more previous visits 31 14.0
*All columns do not sum to 224 due to missing data
Table 3 Participant willingness for use of tissue samples
Number (%)




Depends on tissue type 6 2.7




*Branching for responses of ‘No’ to first question “If asked, would you allow
your left-over tissue to be used in a research study approved by an ethics
committee?” means that 17 participants skipped the following question
regarding storage of left-over tissue. An additional 15 participants did not
provide a response for the question regarding storage of left-over tissue
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Permission
Of the 194 participants who provided data regarding
permission, 71 % preferred a system where individuals
only need to be asked once for permission for use of
their stored samples. Twenty-one percent of participants
preferred a system where consent was sought each time
the sample was used, and 8.2 % believed that the individ-
ual should decide what type of permission they would like
to provide.Linking with medical records
Of the 195 participants that provided data regarding
linkage, approximately two-thirds (62 %) indicated a pref-
erence for their sample to be linked with their medical
records, 29 % had no preference and 9.2 % preferred their
sample to be unlinked.
Feedback of research results
Of the 165 participants that provided data regarding
feedback of results, 79 % wanted to receive general infor-
mation about the results of research in which their tissue
sample was used. Fourteen percent of participants did
not want to receive information and 7 % were unsure.
Discussion
Despite the critical role tissue banking plays in advancing
biomedical science and translational research, little re-
search has specifically explored cancer patient perspec-
tives on contributing to tissue banks. To our knowledge,
this study is one of only a few which have quantitatively
examined the views of patients with cancer, and the first
to explore the views of Australian patients. This study ex-
plored patients’ willingness to donate tissue, the factors
that influence decisions to donate, and patient preferences
for providing consent. Understanding patient preferences
about these issues has the potential to facilitate consent
processes and the development of acceptable protocols for
communication from tissue banking programs to donors.
Consistent with oncology patient preferences from
qualitative work [6], the majority of patients in this study
(84 %) indicated they were willing for their tissue to be
used in an approved research project, of which 96 %
indicated they would allow any leftover tissue to be used
in future research projects. Based on our study, the
willingness of Australian patients with cancer to donate
to biobanks appears slightly higher than that of the
Table 4 Factors influencing participant decisions for use of tissue samples (n = 182*)
Yes n (%) No n (%) Unsure n (%)
Sense of duty to take part for the benefit of future patients (n = 182) 149 (82.0) 18 (9.9) 15 (8.2)
Possible benefits to own health (n = 176) 149 (85.0) 14 (8.0) 13 (7.4)
Possible benefits to health of family in the future (n = 181) 160 (88.0) 12 (6.6) 9 (5.0)
Concern refusal would negatively affect relationship with doctors or nurses (n = 172) 14 (8.2) 140 (82.0) 18 (11.0)
Concern refusal would negatively affect health care provided (n = 170) 12 (7.1) 140 (82.0) 18 (11.0)
*All rows do not sum to 182 due to missing data
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sons are difficult due to sample and questionnaire differ-
ences [19]. This might reflect a greater level of altruism in
cancer patients: 88 % reported a desire to contribute to
their family’s future health and 82 % a sense of duty to the
wider community. It is important to note however that
stated willingness to donate to biobanks is not necessarily
reflected by actual donation. Pairwise comparisons be-
tween attitude surveys and actual participation rates from
biobanking organisations are often discordant, with some
biobanks reporting greater donation than willingness, and
others vice versa. For example, among participants at a
breast cancer screening clinic, Lee and colleagues [10]
reported that 66 % indicated they would be willing make a
donation, but only 56 % actually donated material. In the
present study, all participants who indicated they had pre-
viously been approached to donate tissue had consented
suggesting intention to donate and actual donation may
be equivalent in this patient group. The high willingness
to donate provides some support to explore the potential
of ‘opt-out’ models of consent, which should provide a
more cost-effective and time efficient method of tissue
banking. The small proportion of patients (5.8 %) who
remain unsure about donating tissue suggests a need for
future research to explore the reasons for this.
Almost 20 % of participants reported feeling that non-
participation might compromise their relationships with
their doctor. This suggests that some patients will likely
need reassurance from their physician that both their
options for treatment and the quality of care provided
will not be influence or compromised by their decision
to participate or not participate in tissue banking. Pa-
tients and their healthcare providers therefore must have
appropriate time and resources to clearly discuss the
requirements and processes involved in tissue banking
[1, 24]. There have been concerns expressed that clinical
and hospital staff may be too busy to provide appropri-
ate information regarding tissue donation, leaving pa-
tients unsure as to what they are consenting to, and how
their sample might be used [1]. Future research might
consider the provision of appropriate resources to assist
in the discussion of biobanking and to ensure patients
make informed decisions about donation.Consistent with others studies [8, 18], the majority of
participants (71 %) reported a preference for universal
consent for all future research using their donated tissue
sample [8, 18]. However, a greater proportion (21 %) of
participants in the current study preferred to re-consent
each time, only 10 % of participants preferred to re-
consent that reported by Master and colleagues [8]. This
is likely due to the questions used. Master and col-
leagues included an option for ‘tiered consent’. That is,
patients were given a list of the types of studies in which
donated samples could be used, as well as the type of
health information that could be used. Tiered consent
might provide greater certainty for patients that their
samples will only be used in a way that they are comfort-
able with. Moreover, 58 % of participants in the Master
and colleagues study felt that re-consenting each time
was a waste of time and resources, although participants
also reported that re-consenting would increase feelings
of control, trust, and respect with the research team.
The majority (62 %) of participants indicated a prefer-
ence for their donated sample to be linked to their medical
records. That only 62 % were happy to have their sample
linked to their medical records suggests that the additional
benefits of medical record linkage have not been commu-
nicated clearly to potential donors. In addition, most par-
ticipants (79 %) indicated an interest in receiving general
information regarding the results of any study their sample
was used in. Medical record linkage and patient prefer-
ences for the provision of specific information about their
donated sample to be reported back to health care pro-
viders should be explored more closely. Both issues have
ethical implications with respect to maximising the num-
ber of samples that are donated rom patients with cancer.
The use of additional educational and decision support
resources might be of benefit in this context.
Overall, the majority of patients with cancer appear
willing to donate left over tissue to biobanks. These find-
ings suggest that to enhance patient acceptability, tissue
banking programs should:
1. Consider allowing patients to provide one-time,
blanket informed consent, which was preferred by
participants. Additional opt-in consent processes
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more closely in future research;
2. Develop protocols that allow for feedback to donors
that is in line with patient preferences. Feedback
about biobanking research projects and output
might inspire donor confidence and stimulate
further altruism;
3. Provide clear information to potential donors about
who is likely to benefit from their decision to
donate. This is includes highlighting that donors
healthcare is unlikely to experience any direct
benefit as a result of making a donation.
Limitations
These findings must be considered in light of several limi-
tations. First, participants were recruited from two tertiary
medical oncology outpatient clinics in one regional area of
Australia. Findings therefore may not represent the opin-
ions and preferences of cancer patients across Australia.
We recruited only a small sample of Aboriginal and Torres
Strait Islander participants (2.2 % of the total sample),
limiting the generalisability of our findings to this group.
Second, the study was not adequately powered to explore
variation by various disease and treatment factors. It is rea-
sonable to assume there response might differ by factors
including cancer type and stage, and treatment type and
cycle. A larger sample is needed to explore these issues.
Third, this study did not assess patients’ knowledge or
understanding of the processes involved in donating to a
biobank. Although the majority of participants were willing
to donate left over tissue, differences in knowledge of and
experience with biobanking might have biased participants
responses to survey items.
Conclusions
The vast majority of patients with cancer are willing to do-
nate left over tissue to a biobanks, and are willing for that
tissue to be used in future research projects. However,
there appears to be a small proportion of patients who
remain unsure. These findings suggest that to enhance
patient acceptability, tissue banking programs should: (i)
consider allowing blanket informed consent as well as
opt-in models of consent; (ii) develop protocols that allow
feedback of information about donated samples in line
with patient preferences; (iii) provide clear information to
potential donors about the benefits arising from donation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JB, RSF, EF and SA designed the study and were involved in obtaining
ethical approvals. JB, RSF, EF and BH oversaw data collection and data
management. JB, EF and TR oversaw data analysis. All authors were involved
in interpretation of study findings and drafting of the manuscript. All authors
have read and approved the final manuscript.Acknowledgements
Dr Jamie Bryant is supported by an Australian Research Council Post-Doctoral
Industry Fellowship. This research was funded by a Hunter Translational Cancer
Research Unit grant and supported by a Strategic Research Partnership Grant
from the Cancer Council New South Wales to the Newcastle Cancer Control
Collaborative and infrastructure funding from the Hunter Medical Research
Institute. The authors thank all volunteers, including those at the Hunter Medical
Research Institute (Team HMRI), who assisted with data collection. The authors
acknowledge the contribution of staff at Cancer Council New South Wales and
staff within Hunter New England Health and HealthScope, particularly Beverly
Davis, Kelly Randall, Kelly Crawford and Melissa Ledlin.
Author details
1Health Behaviour Research Group, Priority Research Centre for Health
Behaviour, University of Newcastle & Hunter Medical Research Institute, HMRI
Building, University of Newcastle, Callaghan, New South Wales, Australia.
2Hunter Cancer Research Alliance, Hunter Cancer Biobank, Hunter Medical
Research Institute, University of Newcastle and Calvary Mater Newcastle
Hospital, Waratah, NSW 2298, Australia.
Received: 11 September 2014 Accepted: 5 May 2015
References
1. Grizzle WE, Bell WC, Sexton KC. Issues in collecting, processing and storing
human tissues and associated information to support biomedical research.
Cancer Biomark. 2011;9(1):531–49.
2. Riegman PH, Morente MM, Betsou F, de Blasio P, Geary P. Biobanking for
better healthcare. Mol Oncol. 2008;2(3):213–22.
3. Banks E, Herbert N, Mather T, Rogers K, Jorm L. Characteristics of Australian
cohort study participants who do and do not take up an additional
invitation to join a long-term biobank: The 45 and Up Study. BMC Res
Notes. 2012;5(1):655.
4. Johnsson L, Helgesson G, Rafnar T, Halldorsdottir I, Chia K-S, Eriksson S, et al.
Hypothetical and factual willingness to participate in biobank research. Eur J
Hum Genet. 2010;18(11):1261–4.
5. Lewis C, Clotworthy M, Hilton S, Magee C, Robertson MJ, Stubbins LJ, et al.
Public views on the donation and use of human biological samples in
biomedical research: a mixed methods study. BMJ Open. 2013;3(8):1941–6008.
6. Braun KL, Tsark JU, Powers A, Croom K, Kim R, Gachupin FC, et al. Cancer
patient perceptions about biobanking and preferred timing of consent.
Biopreserv Biobank. 2014;12(2):106–12.
7. Vermeulen E, Schmidt MK, Cornel MC, Knoppers BM, van Leeuwen FE,
Aaronson NK. Connective tissue: cancer patients attitudes towards medical
research using excised (tumour) tissue. BioSocieties. 2011;6(4):466–86.
8. Hoeyer K, Olofsson BO, Mjörndal T, Lynöe N. The ethics of research using
biobanks: reason to question the importance attributed to informed
consent. Arch Intern Med. 2005;165(1):97–00.
9. Luque JS, Quinn GP, Montel-Ishino FA, Arevalo M, Bynum SA, Noel-Thomas
S, et al. Formative research on perceptions of biobanking: what community
members think. J Cancer Educ. 2012;27(1):91–9.
10. Lee CI, Bassett LW, Leng M, Maliski SL, Pezeshki BB, Wells CJ, et al. Patients’
willingness to participate in a breast cancer biobank at screening
mammogram. Breast Cancer Res Treat. 2012;136(3):899–906.
11. Budimir D, Polasek O, Marusić A, Kolcić I, Zemunik T, Boraska V, et al. Ethical
aspects of human biobanks: a systematic review. Croat Med J.
2011;52(3):262–79.
12. Greely HT. The uneasy ethical and legal underpinnings of large-scale
genomic biobanks. Annu Rev Genomics Hum Genet. 2007;8:343–64.
13. Rachul C, McGuire A, Caulfield T. Public perceptions and biobanking:
What does the research really say? Studies in Ethics, Law, and Technology.
2012;6(1):97–100.
14. Soto C, Tarrant C, Pritchard-Jones K, Dixon-Woods M. Consent to tissue
banking for research: qualitative study and recommendations. Arch Dis
Child. 2012;97(7):632–6.
15. Murphy J, Scott J, Kaufman D, Geller G, LeRoy L, Hudson K. Public
perspectives on informed consent for biobanking. Am J Public Health.
2009;99(12):2128.
16. World Health Organization. Proposed international guidelines on ethical
issues in medial genetics and genetic service. 2003 19/03/2014]. Available
from: http://www.who.int/genomics/publications/en/index1.html.
Bryant et al. BMC Cancer  (2015) 15:413 Page 8 of 817. Zika E, Schulte In den Bäumen T, Kaye J, Brand A, Ibarreta D. Sample, data
use and protection in biobanking in Europe: legal issues. 2008.
18. Master Z, Claudio JO, Rachul C, Wang JC, Minden MD, Caulfield T. Cancer
patient perceptions on the ethical and legal issues related to biobanking.
BMC Med Genomics. 2013;6(1):8.
19. Critchley CR, Nicol D, Otlowski MF, Stranger MJ. Predicting intention to
biobank: a national survey. Eur J Public Health. 2010;22(1):139–44.
20. Kaufman D, Murphy J, Scott J, Hudson K. Subjects matter: a survey of public
opinions about a large genetic cohort study. Genet Med. 2008;10(11):831–9.
21. Fleming J. Biobanks: Professional, Donor and Public Perceptions of Tissue
Banks and the Ethical and Legal Challenges of Consent, Linkage, and the
Disclosure of Research Results, in Institute for Molecular Bioscience.
Queensland: The University of Queensland; 2007.
22. Cousins G, McGee H, Ring L, Conroy R, Kay E, Croke DT, et al. Public
perceptions of biomedical research: a survey of the general population in
Ireland, Psychology Reports. 2005. p. 8.
23. Kettis-Lindblad O, Ring L, Viberth E, Hansson MG. Genetic research and
donation of tissue samples to biobanks. What do potential sample donors
in the Swedish general public think? Eur J Public Health. 2006;16(4):433–40.
24. Hewitt R, Watson PH, Dhir R, Aamodt R, Thomas G, Mercola D, et al. Timing
of consent for the research use of surgically removed tissue. Cancer.
2009;115(1):4–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
